DE10399031I1 - Rekombinante Viren. - Google Patents
Rekombinante Viren.Info
- Publication number
- DE10399031I1 DE10399031I1 DE2003199031 DE10399031C DE10399031I1 DE 10399031 I1 DE10399031 I1 DE 10399031I1 DE 2003199031 DE2003199031 DE 2003199031 DE 10399031 C DE10399031 C DE 10399031C DE 10399031 I1 DE10399031 I1 DE 10399031I1
- Authority
- DE
- Germany
- Prior art keywords
- recombinant viruses
- viruses
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9071187A | 1987-08-28 | 1987-08-28 | |
US11033587A | 1987-10-20 | 1987-10-20 | |
US18605488A | 1988-04-25 | 1988-04-25 | |
US23439088A | 1988-08-23 | 1988-08-23 | |
PCT/US1988/002816 WO1989003429A1 (en) | 1987-08-28 | 1988-08-24 | Recombinant avipox virus |
Publications (1)
Publication Number | Publication Date |
---|---|
DE10399031I1 true DE10399031I1 (de) | 2004-01-29 |
Family
ID=27492413
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2003199031 Pending DE10399031I1 (de) | 1987-08-28 | 1987-08-24 | Rekombinante Viren. |
DE2003199032 Pending DE10399032I1 (de) | 1987-08-28 | 1987-08-24 | Rekombinante Viren. |
DE3890874A Expired - Lifetime DE3890874C5 (de) | 1987-08-28 | 1988-08-24 | Rekombinante Viren |
DE2002199049 Pending DE10299049I1 (de) | 1987-08-28 | 1988-08-24 | Rekombinante Viren. |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2003199032 Pending DE10399032I1 (de) | 1987-08-28 | 1987-08-24 | Rekombinante Viren. |
DE3890874A Expired - Lifetime DE3890874C5 (de) | 1987-08-28 | 1988-08-24 | Rekombinante Viren |
DE2002199049 Pending DE10299049I1 (de) | 1987-08-28 | 1988-08-24 | Rekombinante Viren. |
Country Status (17)
Country | Link |
---|---|
JP (3) | JP3348156B2 (de) |
KR (1) | KR970011149B1 (de) |
AR (1) | AR241939A1 (de) |
AT (1) | AT408549B (de) |
AU (2) | AU2427588A (de) |
BE (1) | BE1002134A5 (de) |
CH (2) | CH679934A5 (de) |
DE (4) | DE10399031I1 (de) |
DK (1) | DK175904B1 (de) |
FR (1) | FR2621487B1 (de) |
GB (1) | GB2217718B (de) |
IL (1) | IL87581A0 (de) |
IT (1) | IT1229484B (de) |
LU (2) | LU90951I2 (de) |
NL (4) | NL195051C (de) |
NZ (1) | NZ225970A (de) |
WO (1) | WO1989003429A1 (de) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
DE10399031I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
US5286639A (en) * | 1987-09-16 | 1994-02-15 | Nippon Zeon Co., Ltd. | Recombinant avipoxvirus |
DE3813093A1 (de) * | 1988-04-19 | 1989-11-09 | Immuno Ag | Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung |
US5631154A (en) * | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
JP2538367B2 (ja) * | 1988-06-24 | 1996-09-25 | ブリティッシュ・テクノロジー・グループ・リミテッド | Fowlpoxウィルスの非必須領域 |
US5093258A (en) * | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
CA2001001A1 (en) * | 1988-10-21 | 1990-04-21 | Matthew M. Binns | Fowlpox virus promoter |
US6248333B1 (en) | 1990-04-04 | 2001-06-19 | Health Research Inc. | Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD) |
US5204243A (en) * | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
US5514375A (en) * | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
US5756102A (en) * | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
US5503834A (en) * | 1990-11-20 | 1996-04-02 | Virogenetics Corporation | Measles virus recombinant poxvirus vaccine |
IE68404B1 (en) * | 1990-11-20 | 1996-06-12 | Virogenetics Corp | Measles virus recombinant poxvirus vaccine |
US5759841A (en) * | 1990-11-20 | 1998-06-02 | Virogenetics Corporation | Immunological composition of measles virus utilizing recombinant poxvirus |
US5338679A (en) * | 1991-01-08 | 1994-08-16 | Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada | Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter |
US5756101A (en) * | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
EP0575491B1 (de) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Gentechnologisch hergestellter stamm für impfstoffe |
US5766597A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
US5766598A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
AU674491B2 (en) * | 1991-03-20 | 1997-01-02 | Virogenetics Corporation | Recombinant poxvirus malaria vaccine |
EP1156102A1 (de) * | 1991-06-14 | 2001-11-21 | Virogenetics Corporation | Rekombinanter hiv-spezifischer Impfstoff aus Poxvirus |
EP0597016A4 (en) * | 1991-07-26 | 1996-04-24 | Virogenetics Corp | Infectious bursal disease virus recombinant poxvirus vaccine. |
EP0538496B1 (de) * | 1991-08-26 | 2003-10-29 | Baxter Healthcare S.A. | Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken |
US5443831A (en) * | 1991-10-29 | 1995-08-22 | University Of Delaware | Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus |
US5869312A (en) * | 1992-01-13 | 1999-02-09 | Syntro Corporation | Recombinant swinepox virus |
US6497882B1 (en) | 1992-01-13 | 2002-12-24 | Syntro Corporation | Recombinant swinepox virus |
US6033904A (en) * | 1992-01-13 | 2000-03-07 | Syntro Corporation | Recombinant swinepox virus |
JP3706130B2 (ja) * | 1992-01-13 | 2005-10-12 | ヴァイロジェネティクス コーポレイション | マレック病ウイルス組換えポックスウイルスワクチン |
US6127163A (en) * | 1992-01-13 | 2000-10-03 | Syntro Corporation | Recombinant swinepox virus |
US6251403B1 (en) | 1992-01-13 | 2001-06-26 | Syntro Corporation | Recombinant swinepox virus |
US6328975B1 (en) | 1992-01-13 | 2001-12-11 | Syntro Corporation | Recombinant swinepox virus |
JPH08501452A (ja) * | 1992-09-21 | 1996-02-20 | ビアジーン,インコーポレイティド | Felv及び/又はfivに対する組換レトロウィルスベクター |
AU727278B2 (en) * | 1993-02-26 | 2000-12-07 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof II |
US5925358A (en) * | 1993-02-26 | 1999-07-20 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
CA2156423A1 (en) * | 1993-02-26 | 1994-09-01 | Mark D. Cochran | Recombinant fowlpox viruses and uses thereof |
US6136318A (en) * | 1993-02-26 | 2000-10-24 | Cochran; Mark D. | Recombinant fowlpox viruses and uses thereof |
US5496731A (en) * | 1993-03-25 | 1996-03-05 | Xu; Hong-Ji | Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy |
US5843742A (en) * | 1994-12-16 | 1998-12-01 | Avigen Incorporated | Adeno-associated derived vector systems for gene delivery and integration into target cells |
EP0753581A1 (de) | 1995-07-10 | 1997-01-15 | Immuno Ag | Verbesserte rekombinante eukaryotische zytoplasmatische Viren, Methode ihrer Herstellung und ihrer Verwendung als Impfstoffe |
US5858373A (en) * | 1995-12-01 | 1999-01-12 | Virogenetics Corporation | Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them |
AU731860B2 (en) | 1996-07-25 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant pox virus for immunization against tumor-associated antigens |
US6106825A (en) * | 1997-05-07 | 2000-08-22 | University Of Florida | Entomopoxvirus-vertebrate gene delivery vector and method |
WO1999007869A1 (en) * | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
US6248582B1 (en) * | 1997-10-08 | 2001-06-19 | Imran Khan | Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV |
JPH11165762A (ja) | 1997-12-01 | 1999-06-22 | Lintec Corp | チップ体搬送用カバーテープおよび封止構造体 |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
US6602705B1 (en) | 1998-12-31 | 2003-08-05 | Chiron Corporation | Expression of HIV polypeptides and production of virus-like particles |
CA2374610A1 (en) | 1999-06-28 | 2001-01-04 | Jordan J. N. Tang | Catalytically active recombinant memapsin and methods of use thereof |
KR100919916B1 (ko) | 2000-02-23 | 2009-10-07 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 종양 특이적 동물 단백질 |
EP1319069B1 (de) | 2000-06-28 | 2008-05-21 | Corixa Corporation | Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs |
WO2002080982A2 (en) | 2001-01-12 | 2002-10-17 | Chiron Corporation | Nucleic acid mucosal immunization |
ATE318321T1 (de) * | 2001-03-08 | 2006-03-15 | Akzo Nobel Nv | Leporipox-basierende vektorvakzine |
JP4499311B2 (ja) * | 2001-04-27 | 2010-07-07 | シャープ株式会社 | 放送受信端末 |
EP1515982A4 (de) | 2001-05-09 | 2005-10-26 | Corixa Corp | Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs |
US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US20030198621A1 (en) | 2001-07-05 | 2003-10-23 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
DK1581119T3 (da) | 2001-12-17 | 2013-05-13 | Corixa Corp | Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme |
ZA200505302B (en) | 2003-01-06 | 2007-03-28 | Corixa Corp | Certain aminoalkyl glucosaminide phosphate compounds and their use |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
CA2525825A1 (en) | 2003-05-15 | 2005-01-27 | Chiron Corporation | Hiv polynucleotides and polypeptides derived from botswana mj4 |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
EP1804833A2 (de) | 2004-09-22 | 2007-07-11 | GlaxoSmithKline Biologicals SA | Immunogene staphylokokken-zusammensetzungen |
AU2006335256B2 (en) | 2005-11-22 | 2012-10-18 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
US20090081157A1 (en) | 2006-01-09 | 2009-03-26 | Richard Syd Kornbluth | Immunostimulatory Combinations for Vaccine Adjuvants |
US7842299B2 (en) | 2006-03-14 | 2010-11-30 | Oregon Health & Science University | Methods for producing an immune response to tuberculosis |
AU2008221383B2 (en) | 2007-02-28 | 2012-09-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
DK2215269T3 (en) | 2007-10-15 | 2018-03-19 | Admedus Vaccines Pty Ltd | CONSTRUCTION SYSTEM AND APPLICATIONS THEREOF |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
WO2010078556A1 (en) | 2009-01-05 | 2010-07-08 | Epitogenesis Inc. | Adjuvant compositions and methods of use |
US8664183B2 (en) | 2009-02-27 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SPANX-B polypeptides and their use |
WO2011063263A2 (en) | 2009-11-20 | 2011-05-26 | Oregon Health & Science University | Methods for producing an immune response to tuberculosis |
US20130052221A1 (en) | 2010-02-26 | 2013-02-28 | The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services | Dna-protein vaccination protocols |
US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
WO2012106281A2 (en) | 2011-01-31 | 2012-08-09 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
WO2012151272A2 (en) | 2011-05-02 | 2012-11-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
CA2837651A1 (en) | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
CN103717235A (zh) | 2011-06-24 | 2014-04-09 | 埃皮托吉尼西斯有限公司 | 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物 |
US20150004144A1 (en) | 2011-12-02 | 2015-01-01 | The General Hospital Corporation | Differentiation into brown adipocytes |
WO2014035474A1 (en) | 2012-08-30 | 2014-03-06 | The General Hospital Corporation | Compositions and methods for treating cancer |
WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
EP2895191B1 (de) | 2012-09-14 | 2019-06-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Brachyury-protein, adenovirale vektoren zur codierung von brachyury-protein und deren verwendung |
EP2986310B1 (de) | 2013-04-17 | 2020-08-05 | Genzyme Corporation | Zusammensetzungen zur behandlung und vorbeugung von makuladegeneration |
CA2913155A1 (en) | 2013-05-21 | 2014-11-27 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
EP3068783B1 (de) | 2013-11-15 | 2020-09-23 | The Board of Trustees of the Leland Stanford Junior University | Agonisten des hypokretin-rezeptors 2 zur verwendung zur behandlung von herzversagen |
TWI687225B (zh) | 2014-02-06 | 2020-03-11 | 美商健臻公司 | 用於治療及預防黃斑部病變的組成物及方法 |
JP7095990B2 (ja) | 2014-09-18 | 2022-07-05 | シーダーズ-サイナイ メディカル センター | 線維症を治療するための組成物及び方法 |
WO2016154010A1 (en) | 2015-03-20 | 2016-09-29 | Makidon Paul | Immunogenic compositions for use in vaccination against bordetella |
WO2016168601A1 (en) | 2015-04-17 | 2016-10-20 | Khalid Shah | Agents, systems and methods for treating cancer |
CN107708718B (zh) | 2015-04-22 | 2022-01-11 | 西达-赛奈医疗中心 | 用于治疗2型糖尿病的肠内递送的苦味寡肽 |
EP4276106A3 (de) | 2015-05-13 | 2024-01-24 | The United States of America as represented by the Secretary of the Department of Health and Human Services | Methoden und zusammensetzungen beruhend auf konstruktenenthaltend konservierte elemente zur induktion einer immunantwort |
WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
EP3313863B1 (de) | 2015-06-29 | 2020-12-23 | The Board of Trustees of the Leland Stanford Junior University | Degronfusionskonstrukte und verfahren zur steuerung der proteinproduktion |
EP3386593A4 (de) | 2015-12-09 | 2019-07-24 | Admedus Vaccines Pty Ltd | Immunmodulierende zusammensetzung zur behandlung |
WO2018018082A1 (en) | 2016-07-26 | 2018-02-01 | The Australian National University | Immunostimulatory compositions and uses therefor |
US10917454B1 (en) | 2019-08-01 | 2021-02-09 | Rohde & Schwarz Gmbh & Co. Kg | System and method for ATC voice quality assurance |
WO2023070072A1 (en) | 2021-10-21 | 2023-04-27 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Retroelement-generated transcription factor decoys |
WO2023077147A2 (en) | 2021-11-01 | 2023-05-04 | Pellis Therapeutics, Inc. | T-cell vaccines for patients with reduced humoral immunity |
WO2023081756A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2023183588A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Methods of assessing engineered retron activity, and uses thereof |
WO2023183589A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Rt-dna fidelity and retron genome editing |
WO2023183627A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna |
WO2024020346A2 (en) | 2022-07-18 | 2024-01-25 | Renagade Therapeutics Management Inc. | Gene editing components, systems, and methods of use |
WO2024044673A1 (en) | 2022-08-24 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Dual cut retron editors for genomic insertions and deletions |
WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK489481A (da) * | 1980-11-10 | 1982-05-11 | Searle & Co | Plasmidvektor og frmgangsmaade til fremstilling deraf |
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
AU570940B2 (en) * | 1982-11-30 | 1988-03-31 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Process for producing poxvirus recombinants for expression offoreign genes |
FR2563434B1 (fr) * | 1984-04-25 | 1986-07-25 | Transgene Sa | Vaccin contre la rage et procede pour sa preparation |
EP0190254A4 (de) * | 1984-07-05 | 1987-03-09 | Genex Corp | Kloniertes gen, verfahren zu dessen herstellung und seine verwendung. |
DD235669A1 (de) * | 1985-03-26 | 1986-05-14 | Akad Wissenschaften Ddr | Verfahren zur herstellung eines blv-kodierten huellproteins |
WO1986005806A1 (en) * | 1985-03-29 | 1986-10-09 | National Research Development Corporation | Infectious bronchitis virus spike protein |
EP0213894A3 (de) * | 1985-08-23 | 1987-10-21 | Advanced Genetics Research Institute | Defektive Viruspartikelimpfstoffe und Verfahren zur Anwendung derselben |
AU607399B2 (en) * | 1985-09-09 | 1991-03-07 | Cetus Corporation | Infectious recombinant virus vaccine for feline leukemia |
GR862412B (en) * | 1985-09-25 | 1987-01-23 | Oncogen | Vaccines and immuinoassays for acquired immune deficiency syndrome |
AU602875B2 (en) * | 1985-12-18 | 1990-11-01 | British Technology Group Limited | Newcastle disease virus gene clones |
WO1988002022A1 (en) * | 1986-09-22 | 1988-03-24 | Commonwealth Scientific And Industrial Research Or | Recombinant poxviruses |
AU8075787A (en) * | 1986-09-22 | 1988-04-07 | Australian National University, The | Recombinant poxviruses |
EP0261940A3 (de) * | 1986-09-23 | 1989-07-05 | Applied Biotechnology, Inc. | Pseudorabies-Impfstoffe und DNS-Vektoren zur Rekombination mit Poxviren |
DE3853088T2 (de) * | 1987-03-27 | 1995-10-19 | Nippon Zeon Co | Rekombinantes Avipoxvirus. |
DE10399031I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
GB8724885D0 (en) * | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
FR2632863B2 (fr) * | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
JP2538367B2 (ja) * | 1988-06-24 | 1996-09-25 | ブリティッシュ・テクノロジー・グループ・リミテッド | Fowlpoxウィルスの非必須領域 |
WO1990010693A1 (en) * | 1989-03-08 | 1990-09-20 | Health Research, Inc. | Recombinant poxvirus host selection system |
BR9106879A (pt) * | 1990-09-25 | 1993-07-20 | Cantab Pharma Res | Virus mutuante nao retroviral,uso do mesmo,vacina e processo de manufaturar umvirus mutante |
-
1987
- 1987-08-24 DE DE2003199031 patent/DE10399031I1/de active Pending
- 1987-08-24 DE DE2003199032 patent/DE10399032I1/de active Pending
-
1988
- 1988-08-24 AT AT0900788A patent/AT408549B/de not_active IP Right Cessation
- 1988-08-24 CH CH1444/91A patent/CH679934A5/de not_active IP Right Cessation
- 1988-08-24 NL NL8820679A patent/NL195051C/nl not_active IP Right Cessation
- 1988-08-24 DE DE3890874A patent/DE3890874C5/de not_active Expired - Lifetime
- 1988-08-24 KR KR1019890700753A patent/KR970011149B1/ko not_active IP Right Cessation
- 1988-08-24 GB GB8908921A patent/GB2217718B/en not_active Expired - Lifetime
- 1988-08-24 DE DE2002199049 patent/DE10299049I1/de active Pending
- 1988-08-24 JP JP50771588A patent/JP3348156B2/ja not_active Expired - Lifetime
- 1988-08-24 WO PCT/US1988/002816 patent/WO1989003429A1/en active Application Filing
- 1988-08-24 CH CH1652/89A patent/CH679933A5/de not_active IP Right Cessation
- 1988-08-24 AU AU24275/88A patent/AU2427588A/en not_active Abandoned
- 1988-08-28 IL IL87581A patent/IL87581A0/xx not_active IP Right Cessation
- 1988-08-29 NZ NZ225970A patent/NZ225970A/xx unknown
- 1988-08-29 FR FR888811334A patent/FR2621487B1/fr not_active Expired - Lifetime
- 1988-08-29 BE BE8800978A patent/BE1002134A5/fr not_active IP Right Cessation
- 1988-08-29 IT IT8821772A patent/IT1229484B/it active
- 1988-08-29 AR AR88311787A patent/AR241939A1/es active
-
1989
- 1989-04-27 DK DK198902036A patent/DK175904B1/da active Protection Beyond IP Right Term
-
1995
- 1995-04-05 AU AU16288/95A patent/AU690210B2/en not_active Expired
-
2001
- 2001-10-09 JP JP2001311076A patent/JP2002186494A/ja active Pending
-
2002
- 2002-03-15 JP JP2002071416A patent/JP3826055B2/ja not_active Expired - Lifetime
- 2002-09-04 LU LU90951C patent/LU90951I2/fr unknown
-
2003
- 2003-07-09 NL NL300130C patent/NL300130I2/nl unknown
- 2003-09-05 LU LU91039C patent/LU91039I2/fr unknown
- 2003-11-25 NL NL300139C patent/NL300139I1/nl unknown
- 2003-11-25 NL NL300138C patent/NL300138I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10299049I1 (de) | Rekombinante Viren. | |
DK603888A (da) | Rekombinant virus | |
FI892714A (fi) | Rekombinant-coccidiosisvaccin. | |
DE3882144D1 (de) | Gefluegelpocken-virus-promotoren. | |
NO852173L (no) | Rekombinant lymfotoksin. | |
DE3862564D1 (de) | Erdanker. | |
FI882552A0 (fi) | (1h-azol-1-ylmetyl) substituerade benzotriazolderivat. | |
DE3683186D1 (de) | Rekombinantes humaninterleukin-1. | |
DE3785663D1 (de) | Loetgeraet. | |
NO881384L (no) | Peptider. | |
NO885108D0 (no) | Peptider. | |
FI885979A (fi) | Multifrekvensantenn. | |
DE3862309D1 (de) | Aminomethyltetrahydrofurane. | |
ES1006390Y (es) | Gafa mejorada. | |
FI890655A (fi) | Kombinerat handtag/kniv. | |
FI873060A (fi) | Modifierad vaevnads-plasmin-aktivator. | |
FI882741A0 (fi) | Rekombinant htlv-iii-proteiner och deras anvaendning. | |
DE3861543D1 (de) | Knickstab-anordnung. | |
FI895456A0 (fi) | Rekombinant interleukin 2-hybridproteiner. | |
DE3853279T2 (de) | Laryngoskop. | |
DE3861694D1 (de) | Cyclopropancarboxamide. | |
DE3860710D1 (de) | Exklusiv-oder-schaltung. | |
DE3860307D1 (de) | 2-aminomethyltetrahydrofurane. | |
DE3866770D1 (de) | Gerbstoff. | |
DE3867805D1 (de) | Paraocclusaler loeffel. |